EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants

Camille Riff iD, Peter Bold, Maria Heijer, Ryan A Bragg, Danielle Steele, Tina Jellesmark Jensen, Davinder P S Dosanjh, Sabrina I Hanswijk-Bartelds, Esther van Duijn, Elwin R Verheij, Somasekhara Menakuru, Rod Hughes und 1 weitere

British Journal of Clinical Pharmacology · 19.10.2026

DOI: 10.1002/bcp.70844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 19.10.2026. Verfasst von Camille Riff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca Mölndal.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Londamocitinib (AZD4604) is an inhaled, selective Janus kinase 1 (JAK1) inhibitor in development for asthma. This open‐label, two‐part, phase I clinical study (NCT06157255) used a radiolabelled microtracer approach to evaluate the absolute bioavailability and the absorption, distribution, metabolism and excretion (ADME) of inhaled londamocitinib after intravenous and oral administration in healthy male and female participants ( n = 8).

Methods

Pharmacokinetics, safety, metabolic profile and metabolite identification from plasma, urine, and faecal samples were assessed employing highly sensitive accelerator mass spectrometry. Participants received a single oral 4‐mg dose of [ 14 C]londamocitinib (NMT 37.0 kBq [ 14 C]) in Part 1 and an intravenous 30‐μg dose of [ 14 C]londamocitinib (NMT 37.0 kBq [ 14 C]), followed by a single inhaled dose of 3‐mg londamocitinib in Part 2.

Results

Mean recovery of total radioactive material after oral dosing was 76.3% in faeces and 8.7% in urine. After intravenous dosing, recovery was 67.3% in faeces and 16.0% in urine. Absolute bioavailability of oral londamocitinib was 40.4% and for inhaled administration was 62.5%. Unchanged londamocitinib constituted approximately 70% of circulating radioactivity in plasma and accounted for 47.8% and 28.4% of the administered dose in excreta after oral and intravenous administration respectively. No new safety signals were observed.

Conclusion

Following inhaled and oral dosing, londamocitinib demonstrated rapid absorption, and faecal excretion as the principal route of elimination. Unchanged londamocitinib and metabolite M6 were the major entities present in plasma, urine and faeces. Londamocitinib, at these doses, exhibited an acceptable safety and tolerability profile.

Schlagwörter

Stichwörter der Autor:innen

ADMEasthmabioavailabilitylondamocitinibpharmacokinetics

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Drug Metabolism and Pharmacokinetics (DMPK), Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Chemical Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK.
  • Clinical Development, R&I, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Camille Riff

Förderung

  • AstraZeneca Mölndal

Zitieren

APA

Riff, C., Bold, P., Heijer, M., Bragg, R. A., Steele, D., Jellesmark Jensen, T., Dosanjh, D. P. S., Hanswijk-Bartelds, S. I., van Duijn, E., Verheij, E. R., Menakuru, S., Hughes, R., & Dahlbäck, H. (2026). Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70844

Vancouver

Riff C, Bold P, Heijer M, Bragg RA, Steele D, Jellesmark Jensen T, et al. Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70844

BibTeX
@article{Riff2026,
  author = {Riff, Camille and Bold, Peter and Heijer, Maria and Bragg, Ryan A and Steele, Danielle and Jellesmark Jensen, Tina and Dosanjh, Davinder P S and Hanswijk-Bartelds, Sabrina I and van Duijn, Esther and Verheij, Elwin R and Menakuru, Somasekhara and Hughes, Rod and Dahlbäck, Helena},
  title = {Absorption, distribution, metabolism and excretion of londamocitinib after single‐dose inhaled, intravenous and oral administration in healthy participants},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70844}
}
Kostenlos starten →